Charlotta L.
- Country
- Sweden
- Department
- Kardiologen
Research Overview
- Efficacy and Safety Evaluation of ALXN2220 in Adult Patients with Transthyretin Amyloid Cardiomyopathy: A Phase 3 Randomized, Double-blind, Placebo-controlled Study
- Randomized Interventional Trial of Spironolactone and Eplerenone in Heart Failure with Preserved Ejection Fraction Patients
- Evaluation of Sodium Zirconium Cyclosilicate for Optimizing Mineralocorticoid Receptor Antagonist Therapy in Heart Failure with Reduced Ejection Fraction
Data & Insights
Has run more than one trial at 5 of 98 partner sites.
Specializations
Cardiac Amyloidosis
Specializes in investigating therapeutic approaches for Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a progressive cardiac condition affecting adults. The investigator focuses on evaluating novel treatments targeting cardiovascular clinical events and mortality outcomes in this patient population.
- ATTR-CM Management
- Cardiovascular Event Prevention
- Adult Cardiac Care
Heart Failure Management
Conducts research in heart failure with preserved ejection fraction (HFpEF), exploring the effectiveness of mineralocorticoid receptor antagonists. The investigator studies innovative treatment approaches using registry-based clinical trial methodology to assess cardiovascular outcomes.
- HFpEF Treatment Optimization
- Cardiovascular Mortality
- Heart Failure Hospitalization
Advanced Heart Failure Therapy
Explores treatment optimization in heart failure with reduced ejection fraction (HFrEF), with particular attention to managing high-risk hyperkalemia. The investigator examines innovative approaches to optimize mineralocorticoid receptor antagonist therapy in symptomatic patients.
- HFrEF Treatment
- Hyperkalemia Management
- MRA Therapy Optimization
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.